To bring anti-heparanase treatment modalities closer to the clinic, we established a lung cancer PDX model which better resembles the behavior and drug responsiveness of a given cancer patient, and more accurately reflects the clinical heterogeneity of the disease than cell lines [23, 32, 33]. The gene discussed is HPSE; the disease is lung carcinoma.